Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03439267 · ClinicalTrials.gov registry record · NA
Effectiveness of a Proactive Cardiovascular Primary Prevention Strategy, With or Without the Use of Coronary Calcium Screening, in Preventing Future Major Adverse Cardiac Events
A NA study of Cardiovascular Primary Prevention Strategy, sponsored by Intermountain Health Care.
- Active
- Registry status
- NA
- Development phase
- 5,765
- Enrollment target
- 1
- Study location
NCT03439267: Active NA study of Cardiovascular Primary Prevention Strategy, sponsored by Intermountain Health Care.
NCT03439267 is a NA study of Cardiovascular Primary Prevention Strategy that is active but no longer recruiting, run by Intermountain Health Care. The registered enrollment target is 5,765 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (311% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03439267, a NA study of Cardiovascular Primary Prevention Strategy, is active but no longer recruiting, sponsored by Intermountain Health Care.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 5,765 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to test the effectiveness of a proactive cardiovascular primary prevention strategy, with or without the use of coronary calcium screening, compared to current standard care, in preventing future major adverse cardiac events (MACE), including all-cause death, non-fatal myocardial infarction (MI), stroke, or any arterial revascularization among a moderate risk population with no current evidence of cardiovascular disease.
Primary Outcome
Composite of all-cause mortality, myocardial infarction, stroke, and revascularization (coronary, carotid, and peripheral).
Conditions Studied
Interventions
- OTHER Standard Treatment
- COMBINATION_PRODUCT Coronary Artery Calcium Screening and Statin Treatment
Study Locations (1)
Utah
- Intermountain Medical Center and Intermountain Clinics - Murray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,765 participants |
| Start Date | 2018-03-26 |
| Est. Completion | 2027-05 |
| Phase | NA |
What the registry record for NCT03439267 still lists
NCT03439267 is an interventional study that assigns participants to a tested intervention. Its 5,765 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (311% higher).
The record links to 1 condition, with Cardiovascular Primary Prevention Strategy appearing as the primary indexed condition, and to 2 interventions - of which Standard Treatment is the first listed.
NCT03439267 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT03439267 about?
NCT03439267 is a clinical study titled "Effectiveness of a Proactive Cardiovascular Primary Prevention Strategy, With or Without the Use of Coronary Calcium Screening, in Preventing Future Major Adverse Cardiac Events". The primary objective of this study is to test the effectiveness of a proactive cardiovascular primary prevention strategy, with or without the use of coronary calcium screening, compared to current standard care, in preventing future major adverse cardiac events (MACE), including all-cause death, n...
What is the current status of trial NCT03439267?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 5,765 participants. The study started on 2018-03-26. Estimated completion is 2027-05.
What conditions does trial NCT03439267 study?
This clinical trial studies the following conditions: Cardiovascular Primary Prevention Strategy.
What interventions are being tested in trial NCT03439267?
The interventions under investigation include: Standard Treatment (OTHER), Coronary Artery Calcium Screening and Statin Treatment (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03439267?
This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03439267 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03439267's enrollment target sits among peer trials
5,765 24th of 2000 higher than 1,977 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04983875 · 5,708 participants · NA
Mammography and Breast Arterial Calcification: An Information-Sharing Trial
- NCT06627335 · 5,621 participants
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
- NCT05636176 · 5,600 participants · Phase 3
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
- NCT06981598 · 5,586 participants · NA
Prevention of Psychological Health Problems Via Integrated Operational Support
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI